Nkarta, Inc.
NASDAQ:NKTX · NASDAQ Global Select
+$0.10 today
Vol 0.34M · Avg 0.76M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+44.75%
Period High
$3.49
Period Low
$1.66
Latest
$2.62
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Forte Biosciences, Inc.
NASDAQ:FBRX
$243.83M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Cassava Sciences, Inc.
SAVA
$63.77M
Applied Therapeutics, Inc.
APLT
$14.86M
What is the latest NKTX filing?
The latest filing shown is 4 dated Jun 11, 2026.
How many recent filings does NKTX have?
Intrinsic Alpha currently shows 20 recent filings for NKTX.
Explore More
Continue the stock analysis
Jump to another research area for this company.